MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral.

MHRA-100349-PIP01-21-M03

Scope of the Application

Active Substance(s)

REZAFUNGIN ACETATE

Condition(s)

Treatment of invasive candidiasis

Pharmaceutical Form(s)

Powder for concentrate for solution for infusion; Age-appropriate dosage form for parenteral use.

Route(s) of Administration

INTRAVENOUS USE

Name / Corporate name of the PIP applicant

Napp Pharmaceuticals Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Napp Pharmaceuticals Limited submitted to the licensing authority on 30/04/2025 11:47 BST an application for a Modification

The procedure started on 11/06/2025 10:38 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100349-PIP01-21-M03

Of 21/07/2025 10:48 BST

On the adopted decision for REZAFUNGIN ACETATE (MHRA-100349-PIP01-21-M03) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan).

This decision applies to a Modification for REZAFUNGIN ACETATE, Powder for concentrate for solution for infusion; Age-appropriate dosage form for parenteral use. , INTRAVENOUS USE .

This decision is addressed to Napp Pharmaceuticals Limited, Cambridge Science Park, Milton Road, Cambridge, UNITED KINGDOM, CB4 0GW

ANNEX I

1. Waiver

1.1 Condition:

Not applicable.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of invasive candidiasis

2.2 Indication(s) targeted by the PIP:

Treatment of invasive candidiasis

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than 18 years of age.

2.4 Pharmaceutical Form(s):

Powder for concentrate for solution for infusion Age-appropriate dosage form for parenteral use

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of an age appropriate dosage form for parenteral use suitable for the paediatric population from birth with polysorbate 80 level safe for young infants.
Non-Clinical Studies	3	Study 4 Single dose juvenile toxicokinetic study in rats. Study 5 Dose-range finding juvenile toxicity study in rats. Study 6 Definitive juvenile toxicity study in rats.
Clinical Studies	2	Study 2 This study was deleted during procedure MHRA-100349-PIP01-21-M03. Study 3 This study was deleted during procedure MHRA-100349-PIP01-21-M03. Study 7 (MR907-2503) This study was added during procedure MHRA-100349-PIP01-21-M03. Open-label, uncontrolled trial to evaluate safety, tolerability, PK and activity of rezafungin acetate for prevention of invasive candidiasis in immunocompromised children from birth to less than 18 years of age. Study 8 This study was added during procedure MHRA-100349-PIP01-21-M03. Open-label, uncontrolled trial to evaluate safety, tolerability, PK and activity of rezafungin acetate in children from birth to less than 18 years of age with suspected or confirmed invasive candidiasis.
Extrapolation, Modeling & Simulation Studies	1	Study 9 This study was added during procedure MHRA-100349-PIP01-21-

		M03. Population PK modelling of rezafungin acetate to confirm the paediatric posology from birth to less than 18 years of age.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	30/04/2030
Deferral of one or more studies contained in the paediatric investigation plan:	Yes